COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN COMPARED TO ATORVASTATIN IN SPANISH PATIENTS AT MODERATE, HIGH, AND VERY HIGH CARDIOVASCULAR RISK

被引:0
作者
Garcia-Goni, M. [1 ]
Facila, L. [2 ]
Cinza, S. [3 ]
Pinto, X. [4 ]
Cortes, X. [5 ]
Prades, M. [6 ]
Aceituno, S. [6 ]
机构
[1] Univ Complutense, Madrid, Spain
[2] Hosp Gen Univ Valencia, Valencia, Spain
[3] Porto Do Son Primary Care Hlth Ctr, La Coruna, Spain
[4] Hosp Bellvitge Princeps Espanya, Lhospitalet De Llobregat, Spain
[5] Almirall SA, Barcelona, Spain
[6] Outcomes 10, Castellon De La Plana, Spain
关键词
D O I
10.1016/j.jval.2018.09.620
中图分类号
F [经济];
学科分类号
02 ;
摘要
PCV74
引用
收藏
页码:S104 / S105
页数:3
相关论文
共 50 条
[31]   THE EFFECTIVENESS OF ROSUVASTATIN IN HIGH RISK PATIENTS TREATMENT [J].
Kuznetsova, T. ;
Gavrilov, D. ;
Kirillova, A. ;
Dudanov, I. .
ATHEROSCLEROSIS SUPPLEMENTS, 2008, 9 (01) :221-222
[32]   Cost-effectiveness analysis of a cardio-oncology rehabilitation framework compared to an exercise intervention for cancer survivors with high cardiovascular risk [J].
Viamonte, Sofia G. ;
Tavares, Aida ;
Alves, Alberto J. ;
Joaquim, Ana ;
Vilela, Eduardo ;
Capela, Andreia ;
Costa, Ana Joao ;
Duarte, Barbara ;
Rato, Nuno Dias ;
Afreixo, Vera ;
Carvalho, Ricardo Fontes ;
Santos, Mario ;
Ribeiro, Fernando .
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2024,
[33]   Screening for second primary melanoma in high risk patients: A cost-effectiveness analysis [J].
Seth, Divya ;
Krasne, Margaret ;
James, Lyndon ;
Kim, Jane ;
Bordeaux, Jeremy .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) :AB2-AB2
[34]   Analysis of Effectiveness and Safety of Romosozumab in Patients with Very High Risk of Fracture in a Spanish Population [J].
Moreno Garcia, Marina Soledad ;
Gonzalez Mazario, Roxana ;
Uson Rodriguez, Yedra ;
Merino Ibarra, Erardo ;
Giner, Emilio ;
Cobeta Garcia, Juan Carlos ;
Arce Benavente, Marilia ;
Fabregas Canales, Maria Dolores ;
Ullier Bellmunt, Julia ;
Boselli, Giuliano ;
Martinez Valles, Pilar ;
Fragio Gil, Jorge Juan ;
Vazquez Galeano, Carlos ;
Turrion Nieves, Ana .
ARTHRITIS & RHEUMATOLOGY, 2024, 76 :4326-4328
[35]   Effects of atorvastatin and rosuvastatin on renal function in patients at high cardiovascular risk: a meta-analysis of 21 randomized trials [J].
Savarese, G. ;
Volpe, M. ;
Musella, F. ;
Casaretti, L. ;
Perrone-Filardi, P. .
EUROPEAN HEART JOURNAL, 2012, 33 :950-950
[36]   COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AT HIGH CARDIOVASCULAR RISK IN POLAND [J].
Pawlik, D. ;
Wojcik, R. ;
Zawodnik, A. ;
Kaczor, M. P. .
VALUE IN HEALTH, 2017, 20 (09) :A478-A478
[37]   Rosuvastatin is more cost-effective compared to atorvastatin and simvastatin for hyperlipidemia management in high-risk patients in routine clinical practice [J].
Ohsfeldt, RL ;
Gandhi, SK ;
Fox, KM ;
Stacy, T ;
McKenney, JM .
VALUE IN HEALTH, 2006, 9 (03) :A123-A123
[38]   COST-EFFECTIVENESS OF ALIROCUMAB FOR PATIENTS WITH HYPERCHOLESTEROLEMIA AT HIGH CV RISK [J].
Yang, M. C. ;
Tan, E. C. H. .
VALUE IN HEALTH, 2019, 22 :S128-S128
[39]   The cost-effectiveness of preoperative optimisation of high risk surgical patients [J].
AN Chamberlain ;
N Harper ;
S Morris .
Critical Care, 6 (Suppl 1)
[40]   THE COST-EFFECTIVENESS OF TAVI IN INOPERABLE AND HIGH RISK PATIENTS IN FRANCE [J].
Goodall, G. ;
Zemanova, B. ;
Candolfi, P. ;
Sohlberg, A. .
VALUE IN HEALTH, 2017, 20 (09) :A589-A589